血管炎市場：現況分析與預測（2023-2030）

由於血管炎治療技術不斷進步，包括基因組技術的進步，預計血管炎市場在預測期內將以 3.5% 的複合年增長率強勁增長。 例如，2023年7月，罕見免疫疾病酵素技術先驅Hansa Biopharma宣布，研究者發起的抗中性粒細胞胞漿抗體相關性血管炎2期試驗中的第一位患者接受了imrifidase治療。他宣布，他已接受治療。 其他幾個因素也促進了市場的快速擴張，包括研究投資的增加、生物製劑的更多採用、人均收入的增加、醫療保健支出的擴大以及患者治療效果的改善。 例如，根據醫療保險和醫療補助服務中心的數據，2021 年美國醫療保健費用增加了 2.7%，達到每人 12,914 美元。

依藥物類型劃分，市場分為生物製劑、皮質類固醇和免疫抑制劑。 由於其高效且易於獲取，皮質類固醇細分市場在 2022 年佔據了最高的市場份額。 此外，皮質類固醇如潑尼松和甲基潑尼松龍由於其速效特性，多年來用於治療血管炎的消耗量不斷增加。 例如，為了給 ANCA 相關血管炎患者有效的治療，ChemoCentryx, Inc. 於 2020 年 7 月要求美國食品和藥物管理局 (FDA) 減少與日常服用類固醇相關的毒性並改善患者的治療結果。皮質類固醇的新藥申請(NDA)，可改善 其他因素，例如老年人口的增加，也正在加強皮質類固醇細分市場的基礎。

依疾病類型，市場分為小血管、中血管和大血管。 由於全球小血管動脈瘤病例數量不斷增加，預計小血管血管炎部分在預測期內將以最高的複合年增長率增長。 這種增長得益於化學物質和殺蟲劑使用量的急劇增加。 此外，老年人口的增加正在推動這一領域的成長。 例如，根據社區生活管理局的數據，2014 年，美國有 4,620 萬人年齡在 65 歲或以上，預計到 2060 年將達到 9,800 萬人。 因此，小血管炎病例數的增加正在推動這種模式的發展。

根據分銷管道，市場分為醫院藥房、零售藥房和網路藥房。 2022年醫院藥局品類佔市佔率最高。 此外，醫院提供多種報銷政策，以簡化持續護理的支付流程，從而促進了該細分市場的成長。 此外，隨著醫院和醫療中心數量的增加，世界各地血管炎的盛行率呈上升趨勢，這也促進了這一領域的全球成長。 例如，根據美國醫院協會的統計，到2022年，美國將有大約6,100家醫院，由非營利組織以及州和地方政府營運的社區醫院組成。 因此，醫院藥局領域在2022年仍將維持其市場主導地位。

為了更了解血管炎產業的市場實施情況，市場分為北美（美國、加拿大、北美其他地區）、歐洲（德國、英國、法國、西班牙、義大利、歐洲其他地區）、亞洲太平洋地區（中國、日本、印度及亞太地區其他地區）以及世界其他地區。 預計亞太地區在預測期內將以最高的複合年增長率成長。 有幾個因素正在推動該地區的市場發展，包括血管炎盛行率上升、患者群體龐大、老年人口不斷增加以及研發活動增加。 印度和中國等國家為臨床研究提供了有吸引力的投資機會，預計將積極推動血管炎的研發前景。 除此之外，成年人肥胖率的增加是該細分市場的主要驅動力。 例如，世界衛生組織（WHO）估計，到2021年，東南亞有660萬5歲以下兒童和五分之一的成年人超重，預計未來幾年這一數字將大幅增加。 因此，鑑於亞太地區人口規模龐大，預計在預測期內將以較高的複合年增長率成長。

目錄

第一章市場介紹

• 市場定義
• 主要目標
• 利害關係人
• 限制

第二章研究方法或假設

• 調查過程
• 調查方法
• 受訪者簡介

第三章市場總結

第 4 章執行摘要

第 5 章 COVID-19 對血管炎市場的影響

第 6 章血管炎市場收入（2020-2030 年）

第 7 章按藥物類型劃分的市場洞察

• 生物製劑
• 皮質類固醇
• 免疫抑制劑

第 8 章按疾病類型劃分的市場洞察

• 小血管
• 中型血管
• 偉大的船隻

第 9 章按通路劃分的市場洞察

• 醫院藥房
• 零售藥局
• 網路藥局

第 10 章按地區劃分的市場洞察

• 北美
  • 美國
  • 加拿大
  • 北美其他地區
• 歐洲
  • 德國
  • 英國
  • 法國
  • 義大利
  • 西班牙
  • 歐洲其他地區
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 亞太地區其他地區
• 世界其他地區

第 11 章血管炎市場動態

• 市場驅動因素
• 市場挑戰

第 12 章血管炎市場機會

第 13 章血管炎市場趨勢

第14章需求面與供給面分析

• 需求方分析
• 供給面分析

第 15 章價值鏈分析

第16章競爭場景

• 競爭狀況
  • 波特五力分析

第十七章公司簡介

• AbbVie Inc.
• Amgen Inc.
• Amneal Pharmaceuticals, LLC.
• F. Hoffmann-La Roche Ltd
• GSK plc.
• InflaRx GmbH
• Novartis AG
• Pfizer Inc.
• Staidson Biopharma Inc.
• Teva Pharmaceutical Industries Ltd.

第十八章免責聲明

Vasculitis is a condition where blood vessels including veins, capillaries, and arteries undergo inflammation which causes them to thicken decreasing the diameter of blood vessels. Vasculitis is differentiated into various groups according to the size of the blood vessels they affect. Vasculitis can lead to certain adverse side effects like blockage of blood flow, which could cause organ damage. The vasculitis market is growing at a tremendous rate owing to an increased focus on early detection and prevention, rising research and development activities, a rise in incidences of chronic diseases, advances in treatment options, and a rise in the geriatric population. For instance, in November 2021, a clinical-stage biopharmaceutical company, InflaRx N.V. announced positive results from the European Phase II IXCHANGE study of a first-in-class anti-C5a antibody, vilobelimab, in patients with ANCA-associated vasculitis (AAV).

The Vasculitis Market is expected to grow at a strong CAGR of 3.5% during the forecast period owing to the rising technological advancements for treating vasculitis including advancements in genomic technologies. For instance, in July 2023, Hansa Biopharma, a pioneer in enzyme technology for rare immunological conditions, announced that the first patient was treated with imlifidase in an investigator-initiated phase 2 study in anti-neutrophil cytoplasmic antibody-associated vasculitis. Several other factors such as increased investment in research, increasing adoption of biologics, rising per capita income, expanding healthcare expenditure, and improved patient outcomes are also leading to the surge in the market. For instance, according to the Centers for Medicare & Medicaid Services, U.S. healthcare expenditure grew 2.7% in 2021, reaching USD 12,914 per capita.

Based on drug type, the market is segmented into biologics, corticosteroids, and immunosuppressants. The corticosteroids segment held the highest share in the market in the year 2022 owing to its higher effectiveness and easy availability. Also, the consumption of corticosteroids like prednisone and methylprednisolone has risen over the years for treating vasculitis because of their fasting-acting property. For instance, in July 2020 to provide effective treatment for persons with ANCA-related vasculitis, ChemoCentryx, Inc., suggested US Food and Drug Administration (FDA) to submit a new drug application (NDA) for corticosteroids which will reduce the toxicity associated with daily steroid administration, resulting in better patient outcomes. Other factors such as the rise in the geriatric population are also strengthening grounds for the corticosteroids segment in the vasculitis market.

Based on disease type, the market is segmented into small vessel vasculitis, medium vessel vasculitis, and large vessel vasculitis. The small vessel vasculitis segment is expected to grow with the highest CAGR during the forecast period owing to rising cases of small blood vessel aneurysms globally. This growth has been supported by a surge in the usage of chemicals and pesticides. Also, rising geriatric population is driving the growth of this segment. For instance, according to the Administration for Community Living, 46.2 million people in the U.S. were above the age of 65 in 2014 and are estimated to reach 98 million in number by 2060. Thus, the rising cases of small vessel vasculitis are driving the growth of this modality.

Based on the distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies category held the highest share in the market in 2022 attributed to the availability of all required medications at a place. Also, hospitals offer multiple reimbursement policies to ease the payment process for the ongoing medical treatment which facilitates the growth of this segment. Furthermore, rising number of hospitals and healthcare centers, the prevalence of vasculitis has been on the rise around the world, which has contributed to the growth of this segment globally. For instance, according to the American Hospital Association, there were about 6,100 hospitals in the U.S. in 2022, which comprised community hospitals run by non-profit organizations as well as state and local governments. Thus, the hospital pharmacies segment held dominance in the market in the year 2022.

For a better understanding of the market adoption of the vasculitis industry, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. APAC is expected to grow with the highest CAGR during the forecast period. Several factors, such as the rising prevalence of vasculitis, a large patient pool, a rising geriatric population, and rising research and development activities are driving the regional market growth. Countries such as India and China offer attractive investment opportunities for clinical research and are anticipated to positively drive research and development prospects for vasculitis. In addition to this, rising obesity among adults is a major driving factor for this segment. For instance, the World Health Organization in 2021 estimated that in Southeast Asia 6.6 million young children under 5 years and one in five adults are currently overweight, which is expected to significantly rise in upcoming years. Hence, given the large population size of APAC, it is expected to grow with a high CAGR during the forecast period.

Some of the major players operating in the market include: AbbVie Inc.; Amgen Inc.; Amneal Pharmaceuticals, LLC.; F. Hoffmann-La Roche Ltd; GSK plc.; InflaRx GmbH; Novartis AG; Pfizer Inc.; Staidson Biopharma Inc.; Teva Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Vasculitis Market
• 2.2. Research Methodology of the Vasculitis Market
• 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE VASCULITIS MARKET

6 VASCULITIS MARKET REVENUE (USD BN), 2020-2030F

7 MARKET INSIGHTS BY DRUG TYPE

• 7.1. Biologics
• 7.2. Corticosteroids
• 7.3. Immunosuppressants

8 MARKET INSIGHTS BY DISEASE TYPE

• 8.1. Small Vessel Vasculitis
• 8.2. Medium Vessel Vasculitis
• 8.3. Large Vessel Vasculitis

9 MARKET INSIGHTS BY DISTRIBUTION CHANNEL

• 9.1. Hospital Pharmacies
• 9.2. Retail Pharmacies
• 9.3. Online Pharmacies

10 MARKET INSIGHTS BY REGION

• 10.1. North America
  • 10.1.1. U.S.
  • 10.1.2. Canada
  • 10.1.3. Rest of North America
• 10.2. Europe
  • 10.2.1. Germany
  • 10.2.2. U.K.
  • 10.2.3. France
  • 10.2.4. Italy
  • 10.2.5. Spain
  • 10.2.6. Rest of Europe
• 10.3. Asia-Pacific
  • 10.3.1. China
  • 10.3.2. Japan
  • 10.3.3. India
  • 10.3.4. Rest of Asia-Pacific
• 10.4. Rest of World

11 VASCULITIS MARKET DYNAMICS

• 11.1. Market Drivers
• 11.2. Market Challenges

12 VASCULITIS MARKET OPPORTUNITIES

13 VASCULITIS MARKET TRENDS

14 DEMAND AND SUPPLY-SIDE ANALYSIS

• 14.1. Demand Side Analysis
• 14.2. Supply Side Analysis

15 VALUE CHAIN ANALYSIS

16 COMPETITIVE SCENARIO

• 16.1. Competitive Landscape
  • 16.1.1. Porters Fiver Forces Analysis

17 COMPANY PROFILED

• 17.1. AbbVie Inc.
• 17.2. Amgen Inc.
• 17.3. Amneal Pharmaceuticals, LLC.
• 17.4. F. Hoffmann-La Roche Ltd
• 17.5. GSK plc.
• 17.6. InflaRx GmbH
• 17.7. Novartis AG
• 17.8. Pfizer Inc.
• 17.9. Staidson Biopharma Inc.
• 17.10. Teva Pharmaceutical Industries Ltd.

18 DISCLAIMER